ClinicalTrials.gg
Not yet recruitingNCT07575646Updated May 8, 2026

Clinical Evaluation of Self-Adhesive Flowable Giomer With and Without Selective Enamel Etching

An interventional study of Beautifil Flow Plus F00 and FIT SA after selective enamel etching in Cervical Caries, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized clinical trial is to evaluate the clinical performance of the self-adhesive flowable Giomer with and without selective enamel etching compared to flowable Giomer using standard bonding protocol in class V cavity restorations over a period of 18 months.

Read the detailed description

Self-adhesive flowable restorative materials have been introduced to simplify clinical procedures by eliminating the need for separate bonding steps. These materials are designed to combine adhesive and restorative functions in a single application, which may reduce technique sensitivity and chairside time. However, the bond strength of self-adhesive materials to enamel and dentin remains a concern, particularly in cervical lesions where reliable adhesion is critical for long-term clinical success Selective enamel etching has been suggested as a technique to improve enamel bonding when using self-adhesive or self-etch materials, as it enhances micromechanical retention without adversely affecting dentin bonding. Previous studies have reported that additional enamel etching may improve marginal adaptation and retention, while preserving the simplified clinical procedure of self-adhesive systems. Nevertheless, the clinical effectiveness of self-adhesive Giomer materials with and without selective enamel etching in high caries-risk patients has not been sufficiently investigated.

Therefore, randomized clinical trials evaluating the performance of these materials in cervical carious lesions are required to determine the most reliable restorative approach in patients with increased susceptibility to caries.

02

Conditions studied

  • Cervical Caries

Browse trials for

03

In context

Root Caries

39 studies on the registry are indexed under Root Caries; 14 are open to participants now.

This study's planned enrollment of 75 is above the median of 62 across 35 interventional studies indexed under Root Caries.

Browse Root Caries studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cervical carious lesions in anterior teeth and premolars
  2. Small to moderate class V carious lesion (ICDAS 3 \& 4).
  3. Vital upper or lower periodontally sound teeth with no signs of irreversible pulpitis.
  4. Presence of favorable occlusion and teeth are in normal contact with the adjacent teeth

Exclusion criteria

Exclusion Criteria:

  1. Cervical carious lesions in molars.
  2. Deep carious defects (close to pulp, less than 1 mm distance).
  3. Teeth with clinical symptoms of pulpitis such as spontaneous pain or sensitivity to pressure.
  4. Non-vital teeth, Fractured or cracked teeth.
  5. Endodontically treated teeth.
  6. Periodontally affected teeth
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Beautifil Flow Plus F00

    Conventional flowable giomer restorative material with standard bonding protocol

    Other: Beautifil Flow Plus F00

  • Experimental
    FIT SA

    Self-adhesive flowable giomer restorative material

    Other: FIT SA

  • Experimental
    FIT SA after selective enamel etching

    Self-adhesive flowable giomer restorative material after selective enamel etching

    Other: FIT SA after selective enamel etching

Interventions

  • OtherBeautifil Flow Plus F00

    Conventional flowable giomer restorative material

  • OtherFIT SA after selective enamel etching

    using self-adhesive giomer restorative material after selective enamel etching

  • OtherFIT SA

    self-adhesive flowable giomer restorative material

06

What researchers measure

Primary outcomes

  1. Retention

    Modified USPHS criteria

    Time frame: 18 Months

Secondary outcomes

  1. Marginal adaptation, marginal discoloration, secondary caries, and post-operative sensitivity

    Modified USPHS criteria

    Time frame: 18 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — There is no available evidence for assessing FIT SA restorative material in restoration of cervical lesions. Therefore, this study aims to provide valuable insights into the shear bond strength and clinical performance, in terms of the biological, mechanical and esthetic parameters, of FIT SA restorative material in restoration of cervical lesions

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2028, 18 months later.

Of 21 interventional studies with no phase under Root Caries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartEst.
Jul 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575646
Lead sponsor
Cairo University
Responsible party
Nada Abd El Sattar Mohamed Kotb (PhD Candidate, Cairo University) — Principal investigator
First posted
May 8, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion